News - Kamari Pharma

Kamari Pharma > News

Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.

Kamari Pharma Publishes data regarding it’s TRPV3 inhibitors as a potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology

Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium

KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma

Novel TRPV3 inhibitors developed for the treatment of palmoplantar keratodermas, demonstrate safety and efficacy in preclinical models

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology

Kamari Pharma Appoints Dr. John Doux to its Board of Directors

Lichen Simplex Chronicus Itch: An Update

TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome keratinocytes

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund